Short communication

SPECT imaging of nicotinic acetylcholine receptors in nonsmoking heavy alcohol drinking individuals

Irina Esterlis, Kelly P. Cosgrove, Ismene L. Petrakis, Sherry A. McKee, Frederic Bois, Erica Krantzler, Stephanie M. Stiklus, Edward B. Perry, Gilles D. Tamagnan, John P. Seiby, John H. Krystal, Julie K. Staley

Department of Psychiatry, Yale University and VACHS, 950 Campbell Ave, 116A6, Building 5, C305, West Haven, CT 06516, USA

Department of Diagnostic Radiology, Yale University School of Medicine and the Veteran’s Affairs Connecticut Healthcare System (VACHS), West Haven, CT 06516, USA

Institute for Neurodegenerative Disorders, New Haven, CT 06511, USA

Keywords:
Heavy alcohol drinking  
β2*-nicotinic acetylcholine receptors  
SPECT imaging

Abstract

Background: The high rate of comorbidity of tobacco smoking with alcohol drinking suggests common neural substrates mediate the two addictive disorders. The β2*-containing nicotinic acetylcholine receptor (β2*-nAChR) has recently emerged as a prime candidate because some alpha and beta subunit genes have been linked to alcohol consumption and alcohol use behaviors. We hypothesized that β2*-nAChR availability would be altered by alcohol in heavy drinking nonsmokers.

Methods: Eleven heavy drinking (mean age 39.6 ± 12.1 years) and 11 age and sex-matched control (mean age 40.8 ± 14.1 years) nonsmokers were imaged using [123I]-[5-IA-85380 ([123I]-[5-IA]) single photon emission computed tomography (SPECT). Heavy alcohol drinkers drank varied amounts of alcohol (70–428/month) to facilitate exploratory linear analyses of the possible effects of alcohol.

Results: Heavy drinkers consumed on average 9.1 ± 7.3 drinks/occasion; whereas controls drank 1.2 ± 0.9 drinks/occasion. Heavy drinkers were imaged 2.0 ± 1.6 days after last alcoholic beverage. Overall, there were no significant differences in β2*-nAChR availability between the heavy drinking and control nonsmokers. Exploratory analyses of other factors that may be uniquely regulated by alcohol suggested no effects of age, number of alcohol drinks, years drinking, severity of drinking, craving or withdrawal.

Conclusions: These preliminary analyses do not suggest a decrease in receptor availability in heavy drinking nonsmokers as compared to control nonsmokers. However, a larger study is warranted to explore effects of heavy alcohol drinking on other variables, such as sex, smoking, and genetic make up.

© 2010 Published by Elsevier Ireland Ltd.

1. Introduction

The cholinergic system can be altered following alcohol exposure and has been implicated in alcohol use disorders (Hunt and Majchrowicz, 1983; Kochlar and Erickson, 1986), with findings of altered cortical acetylcholine levels in animal and human subjects (Arendt et al., 1983; Beracochea et al., 1986), as well as reduced acetylcholinesterase activity in ethanol-fed rats (Miller and Rieck, 1993). Specific to our research interests, the β2-subunit containing nicotinic acetylcholine receptors (β2*-nAChRs) (Yoshida et al., 1992; Robles and Sabria, 2006), as well as the gene (CHRNA4) that encodes the α4 subunit (Butt et al., 2003), have been implicated in animal models of ethanol use disorders; however, no study has reported examination of this receptor in human alcohol drinkers.

While a specific ethanol binding site on the β2*-nAChR has not been identified, ethanol enhances the association rate of nicotinic agonist binding to nAChRs and can stabilize the nAChR in a non-functional, desensitized state (El-Fakahini et al., 1983). The affinity of agonist binding to the nAChR is enhanced in the presence of ethanol (Forman et al., 1989; Wood et al., 1991). Pretreatment with dihydro-beta-erythroidine (DhbetaE, α4β2-nAChR competitive antagonist) inhibits alcohol uptake (Kuzmin et al., 2008). In rodents, acute alcohol treatment does not alter nAChR number (Collins et al., 1988; Ribeiro-Carvalho et al., 2008); however, prolonged ethanol treatment (5 months) can enhance binding to nAChRs in thalamus and hypothalamus, but decrease binding in hippocampus in male rats (Yoshida et al., 1992). One study reported a 30% increase in nuclear α4β2-nAChR in hippocampus after a 21-week treatment with ethanol (10% solution, w/v) in rats (Robles and Sabria, 2006).
Studies of relationship between ethanol and nAChRs in humans are sparse: an examination in postmortem tissue from human alcoholics failed to demonstrate a difference in \(^{[3]H}\)nicotine binding in thalamus and frontal cortex (Hellstrom-Lindahl et al., 1993). These findings were confounded by assessment of limited brain regions, excessively long postmortem interval (48 ± 4 h) and poor control for comorbid neuropsychiatric disorders, including tobacco smoking. This presents a major caveat because the nicotine in tobacco smoke has very potent regulatory effects on \(\beta_2\)-nAChR, and if nicotine is still present in the brain (which it is up to 7 days post smoking) it interferes with radiotracer binding.

Human laboratory studies provide additional line of support for role of nAChR in alcoholism. Administration of mecamylamine, a nonselective nicotinic antagonist, interferes with the stimulant and euphoric effects of alcohol (Blomqvist et al., 2002; Chi and Wit, 2003; Young et al., 2005). Varenicline, a partial nAChR ago-
nist, reduces alcohol seeking and choice in rats (Steenland et al., 2007), and alcohol craving and self-administration behavior in heavy drinking smokers (Mckee et al., 2009). In addition, the CHRNA2 and CHRNA4 are related to subjective response to alcohol Follow Back Interview (Sobell and Sobell, 1993), and had to consume >70 standardized drinks per month based on Time-
varenicline. In order to participate in the study, heavy drinkers had medications known to act at the nAChRs, e.g., mecamylamine or within 6 months prior to the SPECT study, nor had ever taken any. None of the subjects reported taking any prescription medications in heavy drinkers), or used psychotropic substances for at least 1 year and no marijuana for at least 1 month preceding the study. None of the heavy drinking or control subjects had history or laboratory blood tests, urine drug screen, and electrocardiogram. None of the heavy drinking or control subjects had history or evidence of serious medical or neurological illness, psychiatric dis-
lability was evaluated via structured interview, physical examination, laboratory blood tests, urine drug screen, and electrocardiogram. None of the heavy drinking or control subjects had history or evidence of serious medical or neurological illness, psychiatric dis-

2.1. Participants

This study was approved by the Human Investigational Review Committees at Yale University and West Haven VACHS. Eligibility was evaluated via structured interview, physical examination, laboratory blood tests, urine drug screen, and electrocardiogram. None of the heavy drinking or control subjects had history or evidence of serious medical or neurological illness, psychiatric disorder or substance abuse (except for alcohol dependence/abuse in heavy drinkers), or used psychotropic substances for at least 1 year and no marijuana for at least 1 month preceding the study. None of the subjects reported taking any prescription medications within 6 months prior to the SPECT study, nor had ever taken any medications known to act at the nAChRs, e.g., mecamylamine or varenicline. In order to participate in the study, heavy drinkers had to consume >70 standardized drinks per month based on Time-
line Follow Back Interview (Sobell and Sobell, 1993), and had to have their last alcoholic beverage within 30 days of their SPECT scan. Based on NIH guidelines of percent alcohol by volume of each drink, one standardized drink contains 16.8 mL of alcohol (NIAAA, 2008); therefore, one 12 oz (336 mL) beer, one 5 oz (140 mL) wine, or 1.5 oz (42 mL) liquor are considered as one standardized drink. Control subjects were defined as those who drank <20 drinks per month and no more than 4 drinks per occasion. Other drinking characteristics (age subjects began drinking, total number of drinking years, and family history of alcoholism) were documented. Heavy drinkers were offered a treatment referral upon completing study participation.

Nonsmoking status was defined as smoking <40 cigarettes/lifetime and no cigarette use in the past 6 months, and con-
Nonsmoking status was defined as smoking <40 cigarettes/lifetime and no cigarette use in the past 6 months, and con-
mirmed by breath carbon monoxide levels (<11 ppm) and negligible plasma (≤50 ng/mL) and urinary (<100 ng/mL) cotinine levels at intake and scan days. Women could not be pregnant or breastfeeding to participate in the study. Estrogen and progesterone levels were obtained on the day of SPECT scan.

2.2. Assessments

At baseline screening appointment we administered the Structural Clinical Interview for DSM-IV (SCID-I), and questionnaires to assess alcohol and nicotine dependence and alcohol-related behavior (Fagerstrom Test of Nicotine Dependence—FTND, Tiffany Alcohol Craving Questionnaire, Retrospective Withdrawal Questionnaire), and depressive symptoms (Center for Epidemiological Studies Depression Scale—CES-D). Alcohol withdrawal/craving and depressive symptoms were assessed again on SPECT scan day. Family history of alcoholism was assessed via the self-report (defined positive if 1st degree relatives were diagnosed with alco-

2.3. \(^{[123]I}\)-5-IA SPECT and MRI imaging

2.3.1. SPECT. Participants were imaged as described previously (Staley et al., 2005a). Briefly, \(^{[123]I}\)-5-IA was administered using bolus plus constant infusion paradigm. The average yield was a 55.3 ± 14.7% (n = 22 preparations) and its radiochemical purity was 98.1 ± 1.5%. Three SPECT scans (30 min each) were obtained between 6 and 8 h of infusion, and plasma samples were collected in the middle of second scan to quantify total parent and free fraction (\(f_p\)) of parent tracer in plasma (Zoghbi et al., 2001) and correct for individual differences in metabolism and protein binding of \(^{[123]I}\)5-IA (Cosgrove et al., 2007).

2.3.2. MRI. Magnetic resonance imaging was performed on a Signa 1.5T system (General Electric Co, Milwaukee, WI). Axial images were acquired parallel to the anteroposterior commissural line with an echo time of 5 ms; repetition time of 24 ms; matrix 256 x 192; number of excitations of 1; field of view of 24 cm; and 128 contiguous slices with a thickness of 1.3 mm.

2.4. Image analysis

SPECT emission images were analyzed as described previously (Staley et al., 2005a). Regional \(\beta_2\)-nAChR availability was determined by \(V_T/f_p\) (regional activity/plasma free parent) (Innis et al., 2007), a highly reproducible outcome measure (Staley et al., 2005a). Standard regions of interest were placed on co-registered MRIs and transferred to SPECT images. Regions of interest were chosen based on those known to contain \(\beta_2\)-nAChRs, and included thalamus, striatum (average of caudate and putamen), cerebellum, and pari-
etal, frontal, anterior cingulate, temporal, and occipital cortices. The average of two raters is used for all analyses. Inter-rater was <10% variability between raters across regions.

2.5. Statistical analyses

All analyses were performed using SPSS version 15.0 (SPSS Inc. Headquarters, Chicago, IL). Differences in plasma and brain outcome measures between heavy drinkers and controls were evaluated first using a multivariate analysis of variance (MANOVA) in order to control for experiment-wise Type I error. Correlations
between regional brain $[^{123}]$I-5-IA uptake ($V_t/f_0$) and drinking variables were conducted using Spearman rho ($\rho$) correlation.

3. Results

3.1. Demographics

Demographic variables are reported in Table 1. Eleven (6 men, 5 women; mean age 39.6 ± 12.1 years) heavy alcohol drinking nonsmokers and eleven sex and age-matched (mean age 40.8 ± 14.1 years) control nonsmokers provided written informed consent to participate in this study. Of the heavy drinkers, nine subjects met criteria for current alcohol dependence, and two subjects met criteria for current alcohol abuse. Heavy drinkers were imaged on average 2 days after last drink. There were no significant differences between the control and heavy drinking nonsmokers.

3.2. $\beta_2^*$-nAChR availability and relationship to drinking variables

There was no difference in total radiotracer dose administered between heavy drinking (368.9 ± 2.4 MBq) and control nonsmokers (357.7 ± 36.3 MBq). $[^{123}]$I-5-IA uptake did not differ significantly between heavy drinkers and controls (see Fig. 1), suggesting no overall effect of heavy drinking on $\beta_2^*$-nAChR availability. We observed no association between $[^{123}]$I-5-IA uptake and drinking measures (years of heavy drinking, standardized drinks per month, and days since last drink) in the overall sample of heavy drinkers.

4. Discussion

The present study suggests that there are no significant differences in $\beta_2^*$-nAChR availability between heavy drinking nonsmokers and control nonsmokers in the thalamus, striatum, cerebellum and cortical regions. These findings differ from preclinical studies that suggest an increase in agonist binding to the nAChR after prolonged alcohol exposure (Yoshida et al., 1992; Robles and Sabria, 2006). This difference may be due to differences in regional subunit composition between species. Our results are consistent with a postmortem study that showed no evidence of alteration in $[^{3}H]$nicotine binding to thalamus or cortical nAChRs in deceased alcoholics compared to controls (Hellstrom-Lindahl et al., 1993). Additionally, we did not detect a relationship between drinking variables (years of heavy drinking, standardized drinks per week, and days since last drink) and $\beta_2^*$-nAChR availability. Some preclinical literature suggests there may be a difference between length of alcohol consumption and agonist binding to the nAChRs (Collins et al., 1988; Ribeiro-Carvalho et al., 2008; Yoshida et al., 1992), but this does not appear to be the case in the present sample.

The major limitation of the current study is low sample size. However, this study was designed to be exploratory to determine if there was a possible effect of alcohol, and if receptor availability may relate to alcohol use behaviors or delineate a unique subgroup of drinkers. The study design allowed flexibility in the number of drinks (70–428) consumed per month and in the number of days since last drink (up to 30), to examine associations between $\beta_2^*$-nAChR availability and drinking quantity and frequency, and if there was a change in $\beta_2^*$-nAChR availability over time since last drink. Only nonsmokers were studied to simplify the interpretation of the data because it has been established that the nicotine from tobacco smoke if still in the brain (up to 7–9 days), blocks binding to the receptor and would interfere with a reliable measurement (Staley et al., 2006). However, in a future study we plan to study the effects of alcohol on $\beta_2^*$-nAChR availability in smokers, since some studies show that smoking may have neuroprotective qualities against alcohol’s harmful effect on brain neurochemistry (Staley et al., 2005b; Tizabi et al., 2004; Hetzler and Martin, 2006).

In this study we did not find a relationship between $\beta_2^*$-nAChR availability and days since last drink. The subjects who participated in the current study were imaged during early abstinence (on average within 2 days of last alcoholic beverage). However, long-term abstinence effects of alcohol on $\beta_2^*$-nAChR availability are not known and may differ by smoking status. For example, previous findings from our group showed an upregulation in $\beta_2^*$-nAChR availability in recently abstinent tobacco smokers compared to nonsmokers (Staley et al., 2006); however, this effect is reversed by 6–12 weeks of abstinence when the $\beta_2^*$-nAChR availability appears to normalize (Cosgrove et al., 2009).

---

**Table 1**

| Demographic characteristics for control and alcoholic nonsmokers. |
|-----------------|-----------------|
| Controls, N=11  | Heavy drinkers, N=11 |
| Age*            | 40.8 ± 14.1     |
| Race*           | 8C, 3AA         |
| Years heavy drinking | 0 ± 15.5 ± 13.8 |
| Dranks per episode* | 1.2 ± 0.9      |
| # Drinking days/week* | 0.2 ± 0.8      |
| Days since last drink* | 370 ± 1080.4   |
| CES-D'          | 4.0 ± 5.5       |
| FH+             | 3               |

Abbreviations: Race—AA, African American; C, Caucasian; CES-D, Center for Epidemiological Studies Depression Scale; FH+, family history positive for alcohol.

* Data are presented as mean ± SD.

**Fig. 1.** Scatterplots illustrating individual $[^{123}]$I-5-IA regional distribution volume (regional activity/free plasma parent) determined from the region of interest analyses for each individual subject is illustrated for the thalamus, striatum, and mean cortex (average of parietal, frontal, anterior cingulate, temporal and occipital cortices). Drinkers were imaged on average 2 days after last drink. There were no significant differences between the control and heavy drinking nonsmokers.
Though the genes associated with encoding the nAChRs have been associated with alcoholism, due to the small sample size, we were not able to investigate the relationship between genetic factors and receptor availability in heavy drinking nonsmokers. Specifically, the CHRNA2 and CHRNA4 are related to subjective response to alcohol (Ehringer et al., 2007) and enhancement of nAChR function by ethanol (Butt et al., 2003), respectively, and CHRNA3, but not CHRNA5, is involved in acute locomotor response to alcohol (Kamens et al., 2008). An evaluation of the genetic contribution to $\beta_2$-nAChR expression in human alcohol use disorders is warranted in a larger sample.

To our knowledge, this is the first human neuroimaging study that examines the $\beta_2$-nAChR as a possible neurochemical substrate of alcoholism. Though in the current small sample we did not detect a difference in $\beta_2$-nAChR availability between heavy drinkers and controls, evaluation of this receptor in a more chronic alcoholic sample is warranted.

Role of funding source

The support was contributed by Alcoholic Beverage Medical Research Foundation (ABMRF) and Center for Translational Neuroscience in Alcoholism at Yale University (CTNA, P50 AA012870), National Institute of Health grants R01 DA015577 and K02 DA21863 (Staley), P50 DA13334 and P50 AA15632 (O’Malley), CDA-1 (Esterlis) and NIDA T32 Award. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Alcohol Abuse and Alcoholism, the National Institute on Drug Abuse, or the National Institutes of Health.

Contributors

Irina Esterlis and Kelly P. Cosgrove conducted all MRI and SPECT scan appointments. Irina Esterlis also conducted image and data analysis, literature search, and wrote the manuscript and Kelly Cosgrove aided with manuscript preparation. Ismene L. Petrasik aided in study conceptualization and manuscript preparation. Sherry A. McKee supervised statistical analysis and aided in manuscript preparation. Frederic Bois conducted all the radiolabelling and supervised metabolite analyses. Erica Krantzler conducted data processing and image analysis, as well as data entry. Stephanie M. Stiklus recruited study participants: conducted telephone screens and in-person interviews, and helped with data entry. Edward B. Perry supervised medical evaluations of the potential subjects. Gilles D. Tamagnan aided with radiolabelling and study design, as well as manuscript preparation. John P. Seibyl supervised SPECT data acquisition and aided with medical issues. John H. Krystal aided with study design and completion, study related questions, and manuscript preparation. Julie K. Staley supervised the initial literature search, wrote the protocol, supervised all aspects of the study and aided with manuscript preparation. All authors contributed to and have approved the final manuscript.

Conflict of interest

Conflict of interest from John H. Krystal: During the period of 2007–2009, he served as a scientific consultant to the following companies: Abbott Laboratories, AstraZeneca Pharmaceuticals, Bristol Meyers Squibb, Cypex Bioscience, Forest Laboratories, Glaxo SmithKline, Lohocra Research Corporation, HoustonPharma, Eli Lilly and Company, Pfizer Pharmaceuticals, Schering-Plough Research Institute, SK Life Sciences, Takeda Industries, and Transcept Pharmaceuticals. He holds less than $1000 in exercisable warrant options with Tetragenex Pharmaceuticals. He is the principal investigator of a multicenter study in which Janssen Research Foundation has provided a drug and some support to the Department of Veterans Affairs. He is a co-sponsor for two patents under review for glutamatergic agents targeting the treatment of depression. The remaining authors declare no conflict of interest.

Acknowledgements

The authors gratefully acknowledge Louis Amici and the nuclear technologists at the Institute for Neurodegenerative Disorders for technical assistance. We thank the laboratory of Peter Jatlow, MD, for determining plasma nicotine and cotinine levels. We also thank Dr. Marina Picciotto for conceptual contributions.

References


